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ABSTRACT
Defining a macrophage-tropic phenotype for HIV-1 to assess a role in pathogenesis is complicated by the fact that HIV-1 isolates
vary continuously in their ability to enter monocyte-derived macrophages (MDMs) in vitro, and MDMs vary in their ability to
support HIV-1 entry. To overcome these limitations, we identified consistent differences in entry phenotypes between five paired
blood-derived, T cell-tropic HIV-1 env genes, four of which are CCR5-using (R5) and one of which is CXCR4-using (X4), and
cerebrospinal fluid (CSF)-derived, R5 macrophage-tropic env genes. We performed entry assays using the CD4- and CCR5-in-
ducible Affinofile cell line, expressing a range of CD4 levels that approximates the range from MDMs to CD4 T cells. The mac-
rophage-tropic viruses were significantly better at infecting cells expressing low levels of CD4 than the T cell-tropic viruses from
the same subjects, with the titration of CD4 providing a distinctive and quantitative phenotype. This difference in CD4 utiliza-
tion was not due to macrophage-tropic viruses being CD4 independent. Furthermore, macrophage-tropic viruses did not differ
from paired T cell-tropic viruses in their ability to use low levels of CCR5 (tpaired  1.39; P  0.24) or their use of an alternative
conformation of CCR5. We also infected MDMs with a panel of viruses and observed that infectivity of each virus differed across
four donors and between three preparations from a single donor. We concluded that the evolutionary transition from replica-
tion in T cells to that in macrophages involves a phenotypic transition to acquire the ability to infect cells expressing low levels of
CD4 and that this phenotype is more reliably measured in Affinofile cells than in macrophages.
IMPORTANCE
HIV-1 typically infects memory T cells by using CD4 and CCR5 to enter cells. The virus evolves to infect new cell types by chang-
ing the coreceptor from CCR5 to CXCR4 to infect naive T cells or adapting to the use of low levels of CD4 to infect macrophages.
However, defining the phenotype of macrophage tropism has been difficult due to inherent variability in the use of macrophages
generated in culture to support entry of HIV-1. We describe the use of Affinofile cells with inducible and variable levels of CD4 to
identify a signature phenotype for macrophage-tropic HIV-1. The ability to define HIV-1 variants that have evolved an entry
phenotype that allows more efficient entry into cells with low levels of CD4 sets the stage for a clearer placement of these variants
in HIV-associated pathogenesis.
The HIV-1 Env protein determines the entry phenotype of thevirus, typically using CD4 as the receptor and CCR5 as the
coreceptor. The ability of HIV-1 to replicate in a novel cell type
likely requires adaptation of the viral envelope protein to effi-
ciently utilize the receptor and coreceptor present on that cell
type. The emergence of CXCR4-using virus late in infection has
long been thought to represent adaptation to infect a novel host
cell (reviewed in reference 1), most likely CD4 naive T cells,
which are known to express high levels of CXCR4 and very little
CCR5 (2). This is consistent with a recent in vitro study showing
that receptor-mediated entry of CD4 naive T cells requires use of
the CXCR4 coreceptor (3).
Historically, viruses capable of growing in transformed T cell
lines were called T cell-tropic viruses. Due to the fact that most T
cell lines express CXCR4 but not CCR5, the early isolates capable
of growth on these cell lines were predominantly CXCR4-using
viruses. In order to distinguish these CXCR4-using “T cell-tropic”
viruses, the remaining CCR5-using (R5) isolates were collectively
called “macrophage-tropic” (M-tropic) viruses, based on the ob-
servation that at least some of these isolates could enter and, in
some cases, replicate in macrophages. Thus, the early analyses of
sexually and vertically transmitted HIV-1 suggested that transmit-
ted/founder viruses are predominantly macrophage tropic (4, 5).
These findings were supported by early studies suggesting that
macrophages are the initial target cell for sexual transmission (6)
and by observations that cervical explants could be infected by the
macrophage-tropic virus Ba-L and not by two T cell-tropic strains
(7). More recent studies, however, have contradicted this view-
point by showing that infectious molecular clones (8–10) and env
gene clones (11) generated from transmitted/founder viruses are
predominantly CCR5-using viruses and infect monocyte-derived
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macrophages (MDMs) at levels well below those of prototypic
macrophage-tropic viruses.
Uncertainty about the nature of most R5 viruses also comes
from the study of macrophage-tropic HIV-1. A virus capable of
replicating in MDMs was originally isolated from primary lung
cultures taken from an infant who died of AIDS (12). This virus,
HIV-1Ba-L, was subsequently passaged on MDMs, where it likely
adapted to replication in MDMs in culture. This phenotype has
been linked to the ability to infect cells with low levels of CD4
(13–18), and these types of viruses have most often been found in
brain tissue of subjects who died with neurologic involvement (15,
17, 19–21). However, there are also reports of these viruses being
found in the blood (22, 23). A common observation in studies
using MDMs is that they vary in the capacity to support HIV-1
entry, and this variability is usually dealt with by including several
donors in a study. The lack of a quantifiable phenotype to measure
viruses that enter macrophages with various efficiencies has left
the concept of “macrophage-tropic” viruses vague and inconsis-
tently applied to a wide variety of isolates, thus obscuring the role
of these variants in transmission and pathogenesis.
In this study, we addressed this uncertainty by identifying phe-
notypes that differentiate viruses that have evolved in vivo to rep-
licate in macrophages from those that replicate in T cells. We
accomplished this by examining the entry phenotypes of well-
characterized pairs of macrophage- and T cell-tropic viruses iso-
lated from five subjects, as represented by cloned env genes. The
macrophage-tropic viruses were all derived from cerebrospinal
fluid (CSF), where the virus was previously shown to decay very
slowly after initiation of antiretroviral therapy (24), indicating
that the virus was being produced by long-lived cells, presumably
either perivascular macrophages or microglia (25). In contrast,
the T cell-tropic viruses were blood-derived viruses from the same
subjects and decayed rapidly after the initiation of therapy, indi-
cating that they were being produced by short-lived cells, presum-
ably CD4 T cells. By carefully examining the entry phenotypes of
these viruses, we were able to show that the evolutionary transi-
tion from replication in CD4 T cells to replication in macro-
phages selects for an increased ability to infect cells expressing low
levels of CD4 but does not alter the ability to infect cells expressing
low levels of CCR5. We observed distinctive macrophage-tropic
and T cell-tropic phenotypes by using a CD4 titration curve,
which is possible with the CD4- and CCR5-inducible Affinofile
cell line (26). We also show that infection of MDMs in vitro is an
inconsistent assay for defining a macrophage-tropic phenotype.
As a result, T cell-tropic viruses may appear to be macrophage
tropic when infecting MDMs from some donors/preparations and
T cell tropic on others, and some macrophage-tropic viruses may
show the reverse. Collectively, these studies provide a more quan-
titative definition of HIV-1 macrophage tropism, which will allow
a more accurate identification of these variants that will lead to an
improved understanding of their role in viral pathogenesis.
MATERIALS AND METHODS
Study subjects. In this study, we examined the entry phenotypes of pre-
viously generated env gene clones amplified from the blood and CSF of
subjects infected with HIV-1 subtype B (23). These subjects participated
in a study of HIV-associated dementia (23) at the University of California
at San Francisco. Procedures for sample collection (27), viral decay assays
(24), and cloning (23) (see below) have been described previously. All
samples were collected with written informed consent, and all protocols
were approved by institutional review boards at the collection sites.
Five of these subjects were diagnosed with neurological disease (stages
1 to 3) (Table 1) (23), and we consider the viruses in their CSF to be
M-tropic based on measurements made both in vivo and in vitro. For four
of the subjects (subjects 4013, 4059, 5002, and 7115), the CSF viral load
decayed slowly upon initiation of antiretroviral therapy (24), and the env
clones derived from the CSF mediated the infection of MDMs very effi-
ciently (23), thus indicating that these clones are replicating in long-lived
cells in vivo and are well adapted to entry into macrophages (using viruses
pseudotyped with these Env proteins). Conversely, the blood viral loads of
these subjects declined rapidly after initiation of therapy, indicating pro-
duction from short-lived cells (24), and blood-derived clones from these
subjects mediated the infection of macrophages very poorly, although this
varied by the donor source for the MDMs (23). We consider these clones
to be T cell-tropic viruses and indicate them as R5 (for four of the subjects)
or X4 (for subject 5002) viruses, based on their coreceptor specificity. It is
important to note this distinction of R5 T cell-tropic viruses, which are
typically not accounted for in the literature; however, for simplicity, we
will refer to these five rapid-decay viruses as T cell-tropic without speci-
fying their coreceptor usage. We also included a subject (4051) who had a
mixture of T cell-tropic and M-tropic viruses in the CSF, and we observed
that the M-tropic lineage in the CSF of this subject increased in abundance
relative to the T cell-tropic lineage with the initiation of therapy (unpub-
lished data), consistent with its production from long-lived cells. Thus, we
have a well-validated set of five CSF-derived, M-tropic env clones and
paired blood-derived env clones that represent viruses that were growing
in T cells and the majority of which are CCR5-using. We used these pairs
of clones to develop a quantitative description of CD4 dependence for
entry for two types of viruses: M-tropic and T cell-tropic viruses (see
below).
We also examined env clones from five of these subjects with R5 T
cell-tropic HIV-1 subtype B in the blood and CSF (Table 2). Their blood
and CSF viral loads declined rapidly after the initiation of therapy, and env
clones isolated from both compartments were unable to efficiently infect
macrophages (23). The remaining two subjects were infected with R5 T
cell-tropic HIV-1 subtype C. HIV env clones generated from the blood of
these subjects were unable to infect Affinofile cells expressing low levels of
CD4 (28).
TABLE 1 CD4 sensitivities and fusogenicities of env clones derived from subjects with slow viral decay after initiation of therapyb
Patient
% Infectivity at lowest CD4 density
CD4 usage curve data
Ability to fuse to cells expressing CD4


















4013 0.4 15.9 15.5 19.9 15.7 4.2 3.1 2.6 0.5 83.4 80.9 2.5
4051 1.5 19.7 18.3 20.9 15.3 5.6 3.3 3.9 0.6 86.7 234.3 147.6
4059 0.9 22.8 22.0 17.0 13.6 3.4 3.1 3.1 0.0 43.1 177.9 134.8
5002 1.0 21.4 20.4 18.2 17.9 0.3 2.9 2.3 0.6 24.4 141.9 117.5
7115 0.1 23.5 23.4 24.6 18.6 6.0 3.8 3.2 0.6 14.5 188.9 174.4
a Significant difference between paired CSF and plasma clones (paired t test; P  0.02).
b See Fig. 1A.
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Cloning of env genes. Two env clones—Ba-L and JRCSF—were ob-
tained from the Division of AIDS, NIAID, through the NIH AIDS Re-
search and Reference Reagent Program, Division of AIDS, NIAID, NIH.
The remaining subtype B env clones were generated in a previous study
(23). Here we briefly review the single-genome amplification (SGA) and
cloning procedures. An oligo(dT) primer was used to generate cDNA
from HIV-1 RNA isolated from blood plasma or CSF. SGA (29–31) was
then used to amplify full-length env sequences through the 3= U3 region.
After one round of SGA, amplicons were reamplified, gel purified using a
QIAquick gel extraction kit (Qiagen), and cloned into the pcDNA 3.1D/
V5-His-TOPO expression vector (Invitrogen) by use of a pcDNA 3.1 di-
rectional TOPO expression kit (Invitrogen) and Max Efficiency Stbl2
competent cells (Invitrogen). An additional set of env clones representing
the transmitted virus in the context of heterosexual transmission of sub-
type C HIV-1 (28) was also included in the study of infection of MDMs.
Cells. 293T cells were cultured in Dulbecco’s modified Eagle medium
(DMEM) with 4.5 g/liter glucose (Cellgro) supplemented with 10% fetal
bovine serum (FBS), 50 U/ml of penicillin, and 50 g/ml streptomycin.
Affinofile cells (26) were maintained in DMEM with 4.5 g/liter glucose
(Cellgro) supplemented with 10% dialyzed FBS (12 to 14 kDa; Atlanta
Biologicals) and 50 mg/ml blasticidin (Invitrogen).
At three time points, monocytes were isolated from healthy donors.
Approximately 40 ml of blood was collected from each donor into hepa-
rin-treated tubes. Buffy coats were purified using Ficoll-Paque Plus (GE
Healthcare) following the manufacturer’s directions. We then used neg-
ative selection to isolate monocytes (EasySep human monocyte enrich-
ment kit without CD16 depletion; StemCell Technologies). Monocytes
were resuspended and cultured in RPMI 1640 supplemented with 10%
FBS, 100 mg/ml of penicillin and streptomycin, and 10 ng/ml recombi-
nant human macrophage colony-stimulating factor (M-CSF; Gibco).
Monocytes were then plated at a density of 1.1  106 cells per 60- by
15-mm dish (6 ml medium per dish) for flow cytometry and at 5  104
cells per well of a 48-well plate (0.5 ml medium per well) for infection.
After 5 days, a partial medium change was performed. After an additional
2 days (for a total of 7 days), cells were either infected or processed for flow
cytometry.
Flow cytometry. CD4 and CCR5 expression levels on Affinofile cells,
monocytes, CD4 T cells, and MDMs were quantified using flow cytom-
etry. In order to avoid disrupting surface receptors, Affinofile cells and
MDMs were removed from their culture dishes by nonenzymatic meth-
ods. Affinofile cells were removed using cold phosphate-buffered saline
(PBS; CellGro), and MDMs were removed using cell dissociation buffer
(Gibco). Affinofile cells and MDMs were stained with Fixable Aqua dead
cell stain (Invitrogen) and saturating concentrations of either phycoeryth-
rin (PE)-conjugated anti-human CD4 antibody (clone RPA-T4; BD Bio-
sciences) or PE-conjugated mouse anti-human CCR5 antibody (clone
2D7; BD Biosciences). CD4 expression and CCR5 expression on primary
cells were quantified by staining peripheral blood mononuclear cells (PB-
MCs) with Brilliant Violet 421-conjugated anti-human CD3 antibody
(clone UCHT1; BD Biosciences), allophycocyanin (APC)-Cy7-conju-
gated anti-human CD14 antibody (clone MP9; BD Biosciences), and
saturating concentrations of either PE-conjugated anti-human CD4 anti-
body (clone RPA-T4; BD Biosciences) or PE-conjugated mouse anti-hu-
man CCR5 antibody (clone 2D7; BD Biosciences). QuantiBRITE beads
(BD Biosciences) were then used to translate the mean fluorescence per
cell to the number of CD4 or CCR5 antibody binding sites (ABS) per cell.
Six bead standards of known size (flow cytometry size calibration kit;
Invitrogen) were used to translate measurements of forward scatter into
estimates of cell diameter. All flow cytometry assays were performed using
a Cyan flow cytometer (Beckman Coulter) and analyzed using FlowJo
software (version 9.3.1).
Env-pseudotyped virus stocks. Env-pseudotyped luciferase reporter
viruses were generated by cotransfecting 100- by 20-mm dishes of 293T
cells with 5 g of an HIV-1 env clone, 5 g of pNL4-3.LucR-E plasmid
(obtained from the Division of AIDS, NIAID, through the NIH AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID,
NIH), and 30 l of the FuGENE 6 transfection reagent (Promega). At 5 h
posttransfection, the medium was changed and the cells were incubated at
37°C for an additional 43 h. Viral supernatants were then harvested, fil-
tered through a 0.45-m filter (Millipore), and stored at 80°C. Virus
stocks were not subjected to multiple freeze-thaw cycles.
Affinofile cell assays. Affinofile cells were plated at a concentration of
1.8  104 cells/well in black poly-L-lysine (Sigma)-treated 96-well plates.
After 24 h in culture, ponasterone A (Pon A; Invitrogen) and doxycycline
(Doxy; Sigma) were added at various concentrations to the medium to
induce CD4 and CCR5 expression. Twenty hours later, the medium was
replaced with medium lacking Pon A and Doxy, and virus was added to
the plates. Cells were spinoculated at 2,000 rpm for 2 h at 37°C and then
incubated at 37°C. After 48 h, the cells were washed twice with PBS and
lysed with 50 l of 1 reporter lysis buffer (Promega), and the lysate was
stored at 80°C. Virus entry was then assessed by thawing the lysates and
quantifying luciferase expression by using a luciferase assay system (Pro-
mega).
CD4 usage was examined by infecting Affinofile cells expressing 10
levels of CD4 and a single, high level of CCR5. Affinofile expression of
CD4 ranged from uninduced ([Doxy]  0 ng/ml) to maximally induced
([Doxy]  6 ng/ml), with eight levels in between (0.07, 0.1, 0.2, 0.3, 0.5,
0.7, 1.0, and 1.5 ng/ml Doxy). CCR5 expression was maximally induced
([Pon A]  5 M).
CCR5 usage was examined by infecting maraviroc-treated Affinofile
cells expressing a single, high level of CD4 ([Doxy]  6 ng/ml) and either
a high ([Pon A]  5 M) or low ([Pon A]  0 M) level of CCR5. One
hour prior to spinoculation, maraviroc was serially diluted and added to
cells at 10 concentrations (0, 1.7, 8.2, 41.2, 123.5, 370.4, 1,111.1, 3,333.3,
10,000, and 50,000 nM maraviroc). After spinoculation, the maraviroc-
containing medium was removed from each well and replaced with fresh
medium.
Titration of virus stocks. Virus stocks were titrated by infecting Af-
finofile cells expressing the maximum levels of CD4 ([Doxy]  6 ng/ml)
and CCR5 ([Pon A]  5 M). We then calculated the volume of each
virus stock that generated 800,000 relative light units (RLU) of luciferase
expression when infecting maximally induced Affinofile cells. This quan-
tity of virus, which was in the linear range for measuring infectivity, was
used in all subsequent experiments infecting either MDMs or Affinofile
cells.
Cell-cell fusion assay. A luciferase-based gene reporter assay was used
to assess the ability of Env proteins to mediate cell-cell fusion (32, 33).
Briefly, quail QT6 cells were transfected with individual HIV-1 env ex-
TABLE 2 CD4 sensitivities of env clones derived from subjects with rapid viral decay after initiation of therapya
Patient














4012 1.0 0.6 0.4 24.9 21.0 3.9 3.5 3.0 0.5
4030 0.5 3.1 2.6 21.1 16.9 4.2 3.2 2.9 0.3
4033 1.0 2.3 1.3 16.5 16.8 0.3 3.6 2.5 1.1
5003 1.0 0.5 0.5 17.8 21.5 3.7 3.5 2.9 0.6
7036 0.2 0.8 0.6 19.9 18.8 1.1 6.8 3.5 3.3
a See Fig. 1B.
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pression vectors by using CaPO4 and then infected with a vaccinia virus
expressing T7 RNA polymerase for 18 h. A second population of QT6 cells
was transfected to transiently express human CCR5 and/or human CD4,
or neither; all cells in the second population of QT6 cells were also trans-
fected with the luciferase gene under the control of a T7 promoter and
with a green fluorescent protein (GFP)-expressing vector to monitor
transfection efficiency. The Env-expressing cells were then mixed with the
receptor/coreceptor-expressing cells. Eight hours later, the cells were
lysed, and luciferase expression was measured (represented in figures as
mean RLU) with a luminometer. In this experimental design, luciferase
activity is recorded as a function of the cells expressing the T7 RNA poly-
merase fusing with the cells expressing the luciferase gene under the con-
trol of the T7 RNA polymerase promoter.
Statistical analyses. All statistical analyses were performed using R
statistical software (version 2.14.1). Model fitting of infection data was
performed using the R statistical package (drc) designed to analyze dose-
response models (drm). These analyses fit a four-parameter, log-logistic
model to the data.
RESULTS
Affinofile cells readily distinguish M-tropic and R5 T cell-tropic
viruses based on differences in sensitivity to surface CD4 levels.
Affinofile cells have been engineered to have inducible and
titratable levels of CD4 and CCR5, and they express CXCR4
constitutively. In our previous study, we showed that the ability
to maintain a moderate level of infectivity on Affinofile cells
with the uninduced level of CD4 on the surface was related to
efficient infection of macrophages and the slow decay of viral
load in the CSF (23). Here we explored the phenotype of CD4
dependency across the entire range of CD4 concentrations
available using Affinofile cells. The sensitivity to CD4 level of
viruses pseudotyped with different Env proteins was assessed
by measuring their ability to infect Affinofile cells induced to
express 10 CD4 levels (ranging from 1,425 to 81,649 CD4 mol-
ecules per cell, inferred as antibody binding sites per cell). The
shape of the infectivity curve as a function of CD4 density
(four-parameter, log-logistic curve) differed for comparing the
M-tropic viruses to the R5 (and one X4) T cell-tropic viruses
isolated from the same subject (Fig. 1A; Table 1).
There are three features of these titration curves that distin-
guish the two groups of viruses: (i) the M-tropic viruses retained
the ability to infect cells at the lowest level of CD4 expression
(1,425 CD4 molecules per cell), at 16 to 24% of their infectivity on
high-CD4-expressing cells (81,649 CD4 molecules per cell), while
the T cell-tropic viruses infected Affinofile cells with low levels of
CD4 at only 0 to 2% of their infectivity on high-CD4-expressing
cells (tpaired  14.29; degrees of freedom [df]  4; P value 
0.00014); (ii) the CD4 level that increased infectivity by 50% (CD4
ED50) was significantly lower for the M-tropic viruses than for the
paired T cell-tropic viruses (tpaired  3.84; df  4; P value 
0.018); and (iii) in most cases, the M-tropic virus approached a
plateau level of infectivity at a lower CD4 density than that with
the paired T cell-tropic virus. We observed a similar pattern of
CD4 utilization for the prototypic M-tropic virus Ba-L (data not
shown).
We repeated the above-described assays using T cell-tropic env
clones isolated from the blood and CSF of five subjects who lacked
M-tropic HIV-1 in the CSF (Fig. 1B; Table 2). We observed that
pseudotyped viruses generated using these CSF- and blood-de-
rived env genes did not differ in their minimal ability to infect
Affinofile cells expressing the lowest CD4 level (tpaired  1.25;
df  4; P value  0.28) or in the CD4 level that increased infec-
tivity by 50% (tpaired  0.71; df  4; P value  0.52). Also, there
was no pattern of difference in the approach to a plateau of infec-
tivity at the highest CD4 levels. Thus, the ability to infect cells
expressing low levels of CD4 (and the differences in the other
parameters) is not specific to CSF-derived clones but rather is
specific to the M-tropic clones generated from viruses being pro-
duced in vivo by long-lived cells. Also, we interpret these results to
represent two distinct phenotypes for M-tropic and T cell-tropic
viruses and not simply part of a continuum among isolates in the
ability to use differing densities of CD4.
Titration of CD4 density on Affinofile cells mimics the den-
sities of CD4 on CD4 T cells, macrophages, and monocytes.
Given that Affinofile cells provide a clear phenotypic distinction
between viruses produced in the central nervous system (CNS)
from long-lived cells and viruses present in the blood (Fig. 1A), we
next determined if the density of CD4 on Affinofile cells was sim-
ilar to the density on the target cells for HIV-1 replication. We
used an anti-CD4 antibody to stain CD4 T cells, monocytes,
MDMs, and Affinofile cells either fully induced for CD4 expres-
sion or uninduced (Fig. 2A). The amount of antibody bound to
each cell was estimated by creating a standard curve with a control
set of fluorescent beads. We also estimated the sizes of the cells by
using forward scatter and size standard beads. We found that T
cells and macrophages had similar numbers of CD4 molecules on
the surface but that CD4 T cells were significantly smaller than
MDMs (Fig. 2B). Monocytes had a small number of CD4 mole-
FIG 1 Dose-response curves for infectivity of M-tropic and T cell-tropic vi-
ruses to Affinofile cells expressing various densities of CD4. The sensitivity of
pseudotyped viruses to CD4 levels was assessed by measuring their ability to
infect Affinofile cells expressing 10 CD4 levels (1,425, 4,590, 4,981, 9,374,
22,667, 33,842, 46,204, 58,153, 69,897, and 81,649 CD4 ABS per cell), with
CCR5 fully induced. (A) env genes were isolated from viruses in the blood and
CSF of subjects who had rapid decay of virus in the blood but slow decay of
virus in the CSF with the initiation of anti-HIV-1 therapy (23). These env genes
were used in a transfection protocol to generate pseudotyped viruses that car-
ried a reporter gene (luciferase). Equal amounts of virus were used at each CD4
level, and the level of infectivity at the highest level of CD4 was taken as 100%.
The highest value was within the linear region of the dose-response curve for
infectivity for each virus. The lines for each virus were generated by the R
statistical package (drc) designed to analyze dose-response models (drm). Red
lines represent viruses pseudotyped using env genes generated from viruses in
the blood. Blue lines represent viruses pseudotyped using env genes generated
from viruses in the CSF. (B) A similar analysis was done by comparing viruses
from the blood and CSF of subjects who had rapid decay of virus in both the
blood and CSF after the initiation of therapy (23). The stage designation for
each subject refers to AIDS dementia complex staging, where 0  neurologi-
cally asymptomatic, 1  mild neurological impairment, and 2 and 3  mod-
erate to severe HIV-associated dementia (HAD) (23).
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cules on the surface and also had a small cell diameter, and the
Affinofile cells had a similarly small number of CD4 molecules on
the cell surface in the uninduced state and much higher levels in
the induced state. We normalized the number of CD4 molecules
on the surface by using the surface area of the cell to obtain the
density of CD4 per m2 (Fig. 2C). This showed that the unin-
duced Affinofile cells had a density of CD4 that was severalfold
lower than that on monocytes or MDMs (0.7 versus 3.1 or 3.4 CD4
ABS/m2), and these three cell types were approximately 18- to
90-fold lower in CD4 density than the fully induced Affinofile cells
(64 CD4 ABS/m2). Also, the CD4 density on fully induced Af-
finofile cells approximated but was still less than the density on
CD4 T cells (78 CD4 ABS/m2). Figure 2D summarizes the CD4
densities on the different cell types and shows the approximate
infectivity patterns for M-tropic and T cell-tropic viruses as a
function of CD4 density. These measurements show that the titra-
tion of CD4 on Affinofile cells spans the range of CD4 densities
found on relevant target cells for HIV-1 infection. Composite
CD4 usage curves were generated by fitting a curve to the infec-
tivity data for the five M-tropic clones and fitting a curve to the
infectivity data for the paired, T cell-tropic clones.
Infection of MDMs varies between different MDM cultures.
Infection of MDMs is one definition of macrophage tropism, and
the ability to infect a cell with low levels of CD4 has been used by
some investigators as a surrogate marker for macrophage tropism.
Infectivity of MDMs can be variable, and typically, infections are
repeated with at least two different preparations of MDMs to ac-
count for this variability, although how this variability is then
reconciled is usually not discussed. In an effort to understand the
biological basis for this confounding variability, we infected
MDMs with pseudotyped viruses generated from 14 different env
expression vectors and normalized their infectivity to the infectiv-
ity of the M-tropic virus Ba-L (Fig. 3). We infected a single prep-
aration of MDMs from three donors (Fig. 3A) and three MDM
preparations from one donor (Fig. 3B). As expected, the normal-
ized infectivity of the prototypic R5 T cell-tropic virus JRCSF was
extremely low (0.5 to 2% of that of the M-tropic clone). In con-
trast, some of the T cell-tropic viruses infected the MDMs quite
well. Overall, normalized infectivity of the T cell-tropic viruses
was much lower on MDMs from the donors with the lowest CD4
levels (donors 1 and 4) (Table 3) than on MDMs from the donor
with the highest CD4 levels (donor 3) (Table 3; Fig. 3). Thus,
infection of MDMs from some donors can give a discrepant entry
phenotype compared to the definition obtained using Affinofile
cells.
Macrophage-tropic viruses are able to use low levels of CD4
but are not CD4 independent. It is possible that the residual level
of infectivity seen at the lowest density of CD4 on Affinofile cells is
actually CD4-independent entry. To determine whether the Envs
from the CSF-derived viruses were capable of CD4-independent
entry, we evaluated the ability of these Envs to mediate fusion with
cells expressing CD4 and CCR5 or CCR5 alone. In this assay, one
cell type expresses the receptor and coreceptor, while another cell
type expresses the viral Env protein. Upon mixing of the cell pop-
ulations, the Env protein engages the receptor and coreceptor,
thereby inducing fusion and providing a readout. As a positive
control, we used a lab-derived CD4-independent variant of R3A,
iR3A, that is capable of mediating CD4-independent fusion with
cells expressing only CCR5. As expected, the Env protein from
iR3A mediated fusion of cells expressing CCR5 with or without
CD4, and the Env proteins from the T cell-tropic viruses isolated
from plasma required both CCR5 and CD4 (Fig. 4). Like the Env
proteins from the blood-derived viruses, all of the Env proteins
from the CSF-derived M-tropic viruses required both CCR5 and
CD4 to mediate fusion (Fig. 4). Thus, the residual infectivity at
low CD4 density of the macrophage-tropic viruses is still CD4
dependent. It is worth noting that most of the Env proteins from
the CSF-derived viruses consistently fused cells to a greater extent
than their paired blood plasma-derived counterparts (Table 1)
(tpaired  3.73; df  4; P value  0.02). In a separate experiment
FIG 2 CD4 densities on Affinofile cells approximate the densities of CD4 on CD4 T cells, MDMs, and monocytes. (A) Affinofile cells were either uninduced
or induced to express the highest level of CD4 on the cell surface. Data shown are flow analysis results for uninduced Affinofile cells and fully induced cells. CD4
was quantified as the number of ABS per cell, based on fluorescence calibration using a fluorescent bead standard curve. Cell size was also estimated based on
forward scatter and compared to a bead standard curve. (B) Affinofile cells at the uninduced and induced levels, monocytes, MDMs, and CD4 T cells were
compared by the number of CD4 molecules (ABS) per cell and the cell size, based on diameter. (C) Expression of CD4 as a function of density was plotted for
different cell types (uninduced and induced Affinofile cells, CD4 T cells, monocytes, and MDMs). This analysis shows that uninduced Affinofile cells have a CD4
density that is slightly lower than those of MDMs and monocytes, while fully induced Affinofile cells have a CD4 density that is slightly lower than that of CD4
T cells. (D) Patterns of entry by M-tropic viruses (blue) and T cell-tropic viruses (red), combined from the data in Fig. 1 to generate average dose-response curves
for infectivity as a function of CD4 density. The CD4 densities of monocytes, MDMs, and CD4 T cells are indicated, along with the extremes of CD4 densities
on uninduced and fully induced Affinofile cells.
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(data not shown), we examined QT6 cells transfected with these
constructs and found that they expressed very low CD4 densities
(CD4 ABS/m2). Thus, the observation that CSF-derived Envs are
more active in this fusion assay system is likely due to their ability
to utilize low CD4 densities.
In order to confirm that virus entry into Affinofile cells is CD4
dependent, we performed an additional entry assay in the pres-
ence of an anti-CD4 antibody (leu3a). We treated Affinofile cells
expressing the lowest (uninduced) level of CD4 with the antibody
and found that it blocked both the very low levels of entry dis-
played by T cell-tropic viruses and the higher levels of entry dis-
played by macrophage-tropic viruses (data not shown). Thus, the
enhanced ability of macrophage-tropic HIV-1 to enter cells ex-
pressing low levels of CD4 is not due to CD4-independent entry.
In contrast, the antibody did not reduce entry of vesicular stoma-
titis virus glycoprotein (VSV-G)-pseudotyped HIV-1 (which does
not require CD4 or a coreceptor) and did not completely block
entry of a CD4-independent clone (iR3A) (which requires a core-
ceptor, but not CD4).
M-tropic and R5 T cell-tropic viruses do not differ in the abil-
ity to use low levels of CCR5. In a preliminary study, we examined
whether M- and R5 T cell-tropic viruses differ in the ability to
infect cells expressing a low level of CCR5. We did this by infecting
Affinofile cells expressing high levels of CD4 ([Doxy]  6 ng/ml;
CD4 level  85,055 ABS per cell) and either high levels of CCR5
([Pon A]  5 M; CCR5 level  30,472 ABS per cell) or low levels
FIG 3 Pseudotyped virus infectivity of MDMs differs across both MDM donors and preparations. MDMs were infected with a panel of 14 pseudoviruses: a
prototypic M-tropic virus (Ba-L), a prototypic R5 T cell-tropic virus (JRCSF), two R5 T cell-tropic viruses derived from the blood of individuals infected with
HIV-1 subtype C (28), five R5 T cell-tropic viruses derived from the CSF of individuals infected with subtype B HIV-1 that decayed rapidly after initiation of
antiretroviral therapy (23), and five M-tropic viruses derived from the CSF of individuals infected with subtype B HIV-1 that decayed slowly after initiation of
antiretroviral therapy (23). These pseudotyped viruses were used to infect preparations of MDMs made from the blood of four different donors, drawn and
processed in parallel on the same day (A), and preparations of MDMs prepared from the same donor compared over three different blood donations, each
separated by several months (B). The amount of virus used in the infections was standardized to give the same level of infectivity on fully induced Affinofile cells.
The level of infectivity with the virus pseudotyped with the Ba-L Env protein was used as 100% infectivity, and infectivities of all other viruses were recorded as
percentages of this value.
TABLE 3 Receptor and coreceptor densities on MDMs
Donor
Receptor/coreceptor density (ABS/m2)
Expt 1 Expt 2
CD4 CCR5 CD4 CCR5




FIG 4 The evolution of macrophage tropism does not select for CD4-inde-
pendent entry. QT6 cells were transfected with individual HIV-1 env expres-
sion vectors and infected with a vaccinia virus expressing T7 RNA polymerase.
A second population of QT6 cells was transfected with vectors that express
CCR5 and/or human CD4, or neither, and with a luciferase expression vector.
The two types of cells were then mixed, and 8 h later, the level of luciferase was
measured as an indication of cell fusion. Only the lab-derived positive control
(iR3Ap7cl43) was able to fuse with cells lacking CD4.
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of CCR5 ([Pon A]  0 M; CCR5 level  2,691 ABS per cell) with
our four paired, R5 M-tropic viruses and R5 T cell-tropic viruses.
Reducing CCR5 expression to its uninduced level reduced infec-
tivity by only 0 to 40% and did not reveal any consistent difference
between M- and T cell-tropic viruses (Table 4) (tpaired  1.1;
df  3; P value  0.37).
In order to thoroughly evaluate the sensitivity to CCR5 expres-
sion levels, we chose to treat CD4high CCR5low Affinofile cells with
the CCR5 antagonist maraviroc to titrate the available CCR5 co-
receptor molecules and then infect the cells with M- and T cell-
tropic pseudotyped viruses representing blood- and CSF-derived
viruses from our five experimental subjects (Fig. 5A). We com-
pared the maraviroc sensitivities of the four R5 T cell-tropic vi-
ruses to those of their paired M-tropic viruses (Table 4). Subject
5002 was excluded from this analysis because the T cell-tropic
clone was previously shown to be a CXCR4-using virus (23). We
observed that the remaining four pairs of M- and R5 T cell-tropic
viruses did not differ in the 50% inhibitory concentrations (IC50)
of maraviroc (tpaired  1.55; df  3; P value  0.22) or the slopes
of their maraviroc resistance curves (tpaired  3.13; df  3; P
value  0.052).
We also examined whether the evolution of macrophage tro-
pism selects for viruses capable of using a conformation of CCR5
that is insensitive to maraviroc (Fig. 5B and C). Use of this alter-
native conformation can be observed as partial resistance to mara-
viroc when CCR5 expression levels are high but not when they are
TABLE 4 Parameters describing CCR5 usage when CCR5 levels are lowa
Patient
% Infectivity at lowest CCR5 concn
Maraviroc sensitivity curve data

















4013 86.5 96.0 9.5 10.7 6.8 3.9 0.9 0.7 0.1 1.6 1.1 0.5
4051 65.0 58.6 6.4 2.4 1.0 1.4 1.2 0.9 0.2 0.8 1.2 2.0
4059 132.3 99.6 32.7 10.7 2.8 7.9 0.9 0.8 0.1 1.0 1.5 0.5
5002 79.8 12.0 0.8 2.4
7115 66.7 59.7 7.0 52.4 17.5 34.9 1.3 0.9 0.4 0.0 2.6 2.6
a See Fig. 5A.
FIG 5 The evolution of macrophage tropism does not select for an increased ability to infect cells expressing low levels of CCR5 or the ability to use an alternative
CCR5 conformation. (A) Affinofile cells expressing high CD4 and low/uninduced CCR5 were treated with 10 different concentrations of the CCR5 antagonist
maraviroc (67, 68) and then infected with viruses pseudotyped using the five CSF-derived, M-tropic env clones (blue) and the paired blood-derived, T cell-tropic
env clones (red) from subjects with slow decay of virus in the CSF with the initiation of therapy (as described in the legend to Fig. 1). Differences in sensitivity to
maraviroc were observed only between the blood-derived, CXCR4-using virus from subject 5002 and the paired CSF-derived, CCR5-using virus. The lack of
difference in maraviroc sensitivity between the M- and T cell-tropic viruses shows that the evolution to infect macrophages does not select for the ability to use
lower levels of CCR5. (B and C) The same five R5 M-tropic pseudotyped viruses described for panel A (B) and five R5 T cell-tropic CSF-derived clones (C) were
used to infect Affinofile cells expressing high CD4 and either low CCR5 (4,048 ABS per cell; solid blue lines) or high CCR5 (39,162 ABS per cell; dashed blue lines)
in the presence of 10 different levels of maraviroc. We previously observed that expression of CCR5 at high levels on Affinofile cells results in a population of
CCR5 molecules that can mediate entry for a subset of viruses even in the presence of maraviroc, giving rise to a residual plateau of infectivity in the presence of
the inhibitor (28) and describing an alternative entry phenotype for these viruses. When we compared M-tropic (B) and R5 T cell-tropic (C) pseudotyped viruses
with respect to the ability to use the alternative conformation of CCR5 for entry in the presence of maraviroc, we found no consistent difference among the two
groups of viruses, as indicated by a plateau of resistance in only one M-tropic virus (4051) and one R5 T cell-tropic virus (4030).
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low (28). This type of resistance cannot be explained by use of an
alternative coreceptor (e.g., CXCR4) but rather is due to use of an
alternative CCR5 conformation that is generated when CCR5 is
expressed at high levels. We identified two clones with this type of
resistance. These clones were partially resistant to maraviroc when
infecting CD4high CCR5high Affinofile cells (CD4 level  141,450
ABS per cell; CCR5 level  39,162 ABS per cell) but were sensitive
to maraviroc when infecting CD4high CCR5low Affinofile cells
(CD4 level  141,450 ABS per cell; CCR5 level  4,048 ABS per
cell). One resistant clone was M-tropic (CSF clone from subject
4051), and one was R5 T cell tropic (CSF clone from subject 4030).
Thus, there is no consistent pattern that distinguishes R5 T cell-
tropic viruses from M-tropic viruses in their ability to use this
alternative form of CCR5.
DISCUSSION
Assessing the cellular tropism of HIV-1 is complicated by the fact
that isolates are highly variable in their ability to infect target cells
and target cells vary in their susceptibility to infection. Thus, most
tropism assays do not yield easily interpretable, binary results.
This is well illustrated by studies of macrophage tropism, which
have revealed that viruses can vary up to 1,000-fold in the ability to
infect MDMs (18), with most being capable of some level of infec-
tion (Fig. 3). In addition, our study and other studies have shown
that MDMs are highly variable in their susceptibility to HIV-1
(Fig. 3) (34, 35). These sources of variation mean that assays that
assess infection of MDMs do not yield unequivocal results that
clearly separate HIV-1 variants adapted to growing in CD4 T
cells, with their high levels of CD4, from viruses that have evolved
the ability to grow in cells with low levels of CD4, such as macro-
phages. We have attempted to provide a more rigorous definition
of both an entry assay that can identify the evolutionary step that
allows entry using low levels of CD4 and examples of viruses that
have undergone that evolutionary step to validate the assay.
MDMs themselves are only a representation of the heteroge-
neous populations of cells that collectively represent macrophage-
like cells in the body. The vast majority of macrophages are found
in tissue, where they differentiate either from progenitor cells that
migrated into the tissue during embryonic development or from
blood-derived monocytes (reviewed in reference 36). In the cen-
tral nervous system, for example, microglia are the predominant
macrophage-like cells in the brain parenchyma (37) and are de-
rived from precursors that colonize the brain during embryonic
development (38, 39). Their location allows microglia to survey
the brain for pathogens and to promote brain development and
homeostasis by performing tasks such as synaptic pruning (40)
and phagocytosis of apoptotic neurons (41). In contrast, perivas-
cular macrophages are located in the perivascular (Virchow-
Robin) spaces of blood vessels that traverse the central nervous
system and are derived from monocytes that migrate from the
blood (42). Their position ensures that they are often the first
immune cells that pathogens encounter after breaching the blood-
brain barrier. As a result, they are exposed to more pathogens than
cells elsewhere in the brain and may be more likely to be infected
by HIV-1. Consistent with this possibility, a study of simian im-
munodeficiency virus (SIV)-infected brains found that perivascu-
lar macrophages are infected more often than microglia (43). Sim-
ilarly, the liver has macrophage-like resident cells, i.e., Kupffer
cells, that migrate into the liver during embryonic development
(39, 44) and can have an influx of macrophages as the result of
inflammation. These observations point out that ontogeny and
anatomical location influence macrophage function and, poten-
tially, relevance to infection by HIV-1.
Macrophage function is further affected by the activation state,
which can change rapidly in response to changes in the signaling
environment (reviewed in references 45 and 46). Macrophages
have been classified as either M1 or M2, with activated M1 mac-
rophages having proinflammatory, antimicrobial phenotypes and
M2 macrophages having anti-inflammatory, wound-healing phe-
notypes (reviewed in reference 45). It is now appreciated that even
this dichotomy does not capture the full continuum of macro-
phage phenotypes (47) and that additional macrophage diversity
is generated from the complex signaling environment (47) and
from inherent differences, such as basal gene expression (48), that
alter how cells respond to signals. Together, cellular ontogeny,
signaling environment, activation state, and basal gene expression
generate diverse macrophage populations capable of performing a
variety of functions.
The major function of CD4 is to act as a coreceptor with the T
cell receptor in interactions with antigen-presenting major histo-
compatibility complex (MHC) class II complexes. Since macro-
phages are antigen-presenting cells, the low levels of CD4 that are
expressed on macrophages cannot function in this role. Thus, it is
not clear that the CD4 that is found on macrophages is biologically
significant (for the macrophages), although it has been proposed
(49) that CD4 in this context could serve an alternative function,
as a coreceptor to and enhancer of signaling of Fc	 receptors.
However, CD4 is not detected on macrophages of mice (50), sug-
gesting that its presence is dispensable. There is no information
concerning whether the different types of macrophages and mac-
rophage-like cells in the body, or their different activation states,
vary in the level of surface CD4 expression. Thus, the use of mono-
cytes that are induced to differentiate in cell culture to measure
viral entry phenotypes overly simplifies what is likely to be a much
more complex interaction between HIV-1 and macrophages in
vivo. In our own attempts to examine the levels of CD4 on mac-
rophages, we have found that they can vary between donors (Fig.
3A; Table 3) and in the same donor at different collection times
(Fig. 3B; Table 3). This makes it difficult to ascribe an entry phe-
notype consistent with macrophage tropism. Difficulty in assign-
ing a clear “macrophage-tropic” phenotype has also been re-
viewed by Duncan and Sattentau (51).
How does the range of CD4 densities spanned in our tropism
assay compare to CD4 densities expressed on MDMs and other
potential target cells, at least as represented as primary cells in
culture? A common misconception about macrophages is that
they express fewer CD4 molecules per cell than do T cells, when in
fact they express similar numbers of receptors per cell but express
CD4 at much lower densities (CD4/m2). In this study, we con-
firmed (Fig. 2B) the earlier observation that when exposed to M-
CSF, monocytes can differentiate into macrophages that express
numbers of CD4 molecules similar to those expressed on T cells
(52), but we observed that their large size causes MDMs to have
CD4 densities that are approximately 20-fold lower than those of
T cells (Fig. 2C). Furthermore, we showed that at their unin-
duced level, Affinofile cells express CD4 densities that are
somewhat lower than those of monocytes and MDMs, while at
their maximum induction level they express CD4 densities that
are almost as high as that of T cells (Fig. 2C). Thus, our assay
roughly spans the range of CD4 densities present on macro-
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phages and T cells and reveals differences between viruses
adapted to replication in cells that express very different CD4
densities (Fig. 2D).
While manipulating CD4 densities on Affinofile cells serves as
a tractable system for testing entry phenotypes, accurately assess-
ing those phenotypes also requires defining how true “macro-
phage-tropic” viruses perform within that system. Studies using
other systems have shown that some brain-derived viruses are
capable of replicating in macrophages and have an increased abil-
ity to enter (17, 19, 53) and/or fuse with (16, 53) cells expressing
low levels of CD4. The ability to use low levels of CD4 for entry
(17) has also been observed for a small number of prototypical
macrophage-tropic viruses previously generated by coculturing
lung tissue (BaL) (12), brain tissue (JR-FL) (20), or PBMCs (Ada)
(54) with primary cells or by cloning viruses directly from brain
tissue (YU-2) (55). It is worth considering, however, whether
coculturing with MDMs or PBMCs allowed some of these viruses
to evolve additional phenotypes that do not represent M-tropic
viruses in vivo. We recently observed this for Ba-L, which has a
neutralization-sensitive phenotype (K. T. Arrildt, unpublished
data) that would likely be selected against in vivo. A common
feature of most of these M-tropic clones is that they were not
generated using endpoint dilution PCR to avoid PCR-mediated
recombination of the viral genomes that can obscure their original
sequence organization in vivo.
We previously generated a panel of env genes from viruses that
were validated as being derived from macrophage-tropic variants
by multiple in vivo and in vitro measures, including coming from
a compartmentalized viral population in the CSF/CNS, being pro-
duced from long-lived cells, and being able to infect macrophages
and cells with low levels of CD4 (23, 24). In addition, the env genes
were generated by endpoint dilution to avoid PCR-mediated re-
combination, and in each case the CSF/CNS-derived viruses were
paired with blood-derived viruses from the same subject. We be-
lieve that these viruses are well-validated examples of variants that
can evolve within the CNS in late-stage infection. We found that
these viruses largely fell into two distinct groups: T-tropic viruses
with very low infectivities (2%) when CD4 levels were low and
M-tropic viruses that retained moderately high infectivities
(15%) even with low levels of CD4 (Fig. 1A; Table 1). Differ-
ences in infectivity remained pronounced for viruses infecting
cells expressing all but the highest levels of CD4, as seen by the
M-tropic viruses having significantly lower CD4 ED50 values (Ta-
ble 1). Thus, our assay is a reliable and quantitative method for
distinguishing M- and T-tropic viruses based on their capacity to
infect cells expressing low CD4 densities. Using these types of
assay parameters, we have been able to show that most isolates of
HIV-1, including the transmitted virus (28), require high levels
of CD4 for entry, indicating that most of the time HIV-1 is repli-
cating in CD4 T cells, with their high densities of surface CD4,
and that the virus does not have the entry properties of viruses that
have evolved to infect macrophages. We have been able to identify
rare examples of viruses with intermediate entry phenotypes (56),
although we do not know if this represents phenotypic variation
or evolutionary intermediates. Other investigators have also used
Affinofile cells to identify a low-CD4-density entry phenotype
(57).
We argue that the ability to enter cells with a low density of
CD4 must be the first phenotypic change for a lineage of mac-
rophage-tropic virus, because this mediates the initial step in the
viral life cycle, i.e., entry. There may be other phenotypic adapta-
tions to replication in macrophages, but these will appear linked
on genomes that encode an Env protein that can enter cells with a
low density of surface CD4. This reasoning leads to the conclusion
that an entry phenotype using a low density of CD4 is a necessary
feature of macrophage tropism, although it is not clear if this is the
only viral function that must evolve to allow efficient replication
in macrophages in vivo. Since macrophage-tropic lineages appear
to evolve infrequently, at least with respect to the bulk of viral
replication in CD4 T cells, the normal viral gene products are not
selected for function in macrophages but rather for function in T
cells. Conversely, the use of VSV-G pseudotypes to enhance entry
into macrophages (or other cell types) to assess viral protein func-
tion obscures the fact that the protein being tested likely has not
been selected for function in that cell type.
Do macrophage-tropic viruses ever appear in the blood? We
failed to find macrophage-tropic variants in the blood of 62 sub-
jects with intermediate levels of CD4 T cells (28). However, in
macaques that were depleted of CD4 T cells at the time of infec-
tion, macrophages were easily detected as being infected, and
these animals had relatively high viral loads (58). In macaques
with end-stage disease that were infected with the X4 virus D12,
there was clear evidence of infection of macrophages in the lymph
nodes (59). In a study by Gray et al. (22), viruses isolated from the
blood of patients late in infection (late R5 viruses) were found to
infect macrophages better than viruses isolated early in infection
(early R5 viruses). These late R5 viruses were found to have phe-
notypes similar to those of a prototypical macrophage-tropic virus
(Ada) and were thus inferred to be macrophage tropic. However,
as noted above, the use of MDMs can result in viruses being iden-
tified as macrophage tropic despite being poorly adapted to infect-
ing macrophages in vivo. Thus, the extent to which macrophage-
tropic viruses evolve outside the CNS and reach a significant
fraction of the systemic viral load remains an important question
about HIV-1 pathogenesis.
Do R5 T cell-tropic viruses ever infect macrophages? The fact
that most HIV-1 lineages (in both the CNS and blood) are R5
T-cell tropic suggests that these lineages do not replicate predom-
inantly in macrophages. However, this does not indicate that these
viruses exclusively infect T cells. While macrophage-tropic HIV-1
is better overall at entering MDMs in vitro (Fig. 3), T cell-tropic
viruses can enter MDMs at reduced levels. The effect that inter-
mittent infection of macrophages by T cell-tropic viruses, if it
occurs, may have on pathogenesis or latency is unknown.
We also examined several other entry-associated features of
low-CD4-density entry. Using a cell-cell fusion assay, we were able
to show that both M- and T cell-tropic clones still require CD4 and
a coreceptor (CCR5 in this assay) for entry (Fig. 4), indicating that
the entry activity of M-tropic viruses at low levels of CD4 does not
represent CD4-independent entry. We also found that M-tropic
and T cell-tropic viruses do not differ in the ability to infect cells
expressing low levels of CCR5, their overall sensitivity to CCR5
density (Fig. 5A; Table 4), or their ability to utilize an alternative
conformation of CCR5 (Fig. 5B and C). These findings are con-
sistent with previous studies showing that macrophage tropism is
not related to sensitivity to the CCR5 antagonist TAK-779 (16,
17, 60).
Having a more quantitative assay to define macrophage-tropic
viruses will help to bring clarity to two other relevant issues. First,
viruses with the ability to infect cells with low levels of CD4 create
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independently replicating populations and potentially establish
alternative types of latently infected cells. The observation that
initiating therapy causes these CD4low viruses to slowly decay
within the CSF of most subjects (24) indicates that they are pro-
duced from long-lived, but not immortal, cells within the CNS.
However, it is not known if these cells (macrophages and/or mi-
croglia) can have latent infections that stochastically release virus
over time. If this were a significant reservoir, either in subjects
currently on therapy or after the introduction of purging strategies
for latently infected CD4 T cells, then the rebound virus should
be able to enter cells with low levels of CD4. Second, there are
reports of infection of cells that have no detectable CD4, such as
astrocytes (61) and renal tubular cells (62, 63). It is not clear if
low-level infectivity of these cell types (or other cell types) occurs
with M- or T-tropic HIV-1, although it has been reported that up
to 10 to 20% of astrocytes are infected in vivo (61), despite there
being no evidence that HIV can replicate in these cells (61, 64, 65).
It is important to examine the entry phenotype of viruses reported
to be in these cell types to be able to conceptualize a pathway that
could account for viral entry in the absence of CD4. In this regard,
a report that monocytes in the blood (with their low densities of
CD4) were infected with a virus that was unable to infect T cells
(66) also deserves careful examination, as this type of infection is
the basis for the “Trojan horse” model for introduction of virus
into the CNS.
The use of Affinofile cells to profile the dependence of viruses
on CD4 density to define the entry phenotype will allow for a more
rigorous identification of viral variants that have undergone the
evolutionary step to be able to use low levels of CD4 in viral rep-
lication. Clarifying when and where such viruses evolve will allow
them to be placed more accurately in the context of HIV-1 patho-
genesis and latency. In addition, identifying the cell type in which
a virus is replicating will also allow an appropriate link to be made
between selection for a viral gene product function in the context
of host cell interaction.
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